Search form
Search
contact us
Navigation
home
boards
job center
job ratings
cp wire
device news
pharmagather
catering
advertise
Legal Help
login/register
You are here
Home
»
companies
» Kymriah
Kymriah
ASH: Novartis makes its Kymriah case in follicular lymphoma, but another Gilead showdown awaits
ASH: Novartis makes its Kymriah case in follicular lymphoma, but another Gilead showdown awaits
Fierce Pharma
ASH2020
Novartis
Kymriah
follicular lymphoma
clinical trials
Flag link:
Novartis says CAR-T cancer therapy works in second lymphoma type
Novartis says CAR-T cancer therapy works in second lymphoma type
BioPharma Dive
Novartis
Kymriah
follicular lymphoma
CAR-T
Flag link:
FDA hastens development of Novartis’ Kymriah in follicular lymphoma
FDA hastens development of Novartis’ Kymriah in follicular lymphoma
Pharmaforum
Novartis
Kymriah
follicular lymphoma
FDA
regenerative medicine
Flag link:
Novartis sidesteps Europe travel ban to provide CAR-T drug Kymriah to patients
Novartis sidesteps Europe travel ban to provide CAR-T drug Kymriah to patients
Fierce Pharma
Novartis
Europe
Donald Trump
gene therapy
Kymriah
COVID-19
Flag link:
Novartis still hasn't solved its lingering CAR-T manufacturing issues
Novartis still hasn't solved its lingering CAR-T manufacturing issues
Biopharma Dive
ASH2019
Novartis
FDA
CAR-T
drug manufacturing
Kymriah
Flag link:
Novartis Kymriah demonstrates consistent efficacy and safety outcomes in US patients when used in real-world setting
Novartis Kymriah demonstrates consistent efficacy and safety outcomes in US patients when used in real-world setting
Pharmaceutical Business Review
Novartis
Kymriah
CAR-T
DLBCL
ALL
Flag link:
Celgene posts pivotal CAR-T data ahead of FDA filing
Celgene posts pivotal CAR-T data ahead of FDA filing
Fierce Biotech
Celgene
CAR-T
liso-cel
Kymriah
Yescarta
Flag link:
Expensive Gilead, Novartis cancer therapies losing patients to experimental treatments
Expensive Gilead, Novartis cancer therapies losing patients to experimental treatments
Yahoo/Reuters
lymphoma
Gilead Siences
Novartis
cell therapies
Kymriah
Yescarta
Flag link:
Novartis takes another step forward in global Kymriah rollout as Japan OKs the drug at $305K
Novartis takes another step forward in global Kymriah rollout as Japan OKs the drug at $305K
Endpoints
Novartis
Kymriah
Japan
CAR-T
Flag link:
Medicare would cover CAR-T cell therapies under new CMS proposal
Medicare would cover CAR-T cell therapies under new CMS proposal
Marketwatch
Medicare
CAR-T
cell therapy
CMS
Novartis
Kymriah
Gilead Sciences
Yescarta
Flag link:
Oncology round-up: CAR-T conference raises hopes for solid tumour therapy
Oncology round-up: CAR-T conference raises hopes for solid tumour therapy
Pharmaforum
CAR-T
CAR-T Congress
oncology
Novartis
Kymriah
Europe
Flag link:
Novartis changes NICE's mind on Kymriah, giving CAR-T rival Gilead some company
Novartis changes NICE's mind on Kymriah, giving CAR-T rival Gilead some company
Fierce Pharma
Novartis
Kymriah
CAR-T
UK
diffuse large B-cell lymphoma
Gilead Sciences
Flag link:
Massachusetts Initiative Looks at Payment Plans for Novartis' SMA Gene Therapy
Massachusetts Initiative Looks at Payment Plans for Novartis' SMA Gene Therapy
BioSpace
Massachusetts
Novartis
SMA
gene therapy
Kymriah
Flag link:
Novartis building out cell and gene therapy platform that'll lead the pack, CEO promises
Novartis building out cell and gene therapy platform that'll lead the pack, CEO promises
Fierce Pharma
Novartis
Pharma CEOs
CAR-T
Kymriah
Vas Narasimhan
JPMHC 2019
Flag link:
For CAR-T Cancer Fighters in the Real World, Two Roads Diverge
For CAR-T Cancer Fighters in the Real World, Two Roads Diverge
Xconomy
cancer
CAR-T
Gilead Sciences
Yescarta
Novartis
Kymriah
Flag link:
Novartis seeks to acquire French CAR-T contract manufacturer
Novartis seeks to acquire French CAR-T contract manufacturer
Biopharma Dive
Novartis
M&A
France
CellforCure
CMO
Kymriah
CAR-T
Flag link:
Novartis, still struggling with Kymriah manufacturing, is providing some out-of-spec doses to patients who ask
Novartis, still struggling with Kymriah manufacturing, is providing some out-of-spec doses to patients who ask
Fierce Pharma
Novartis
patients
CAR-T
Kymriah
drug manufacturing
Flag link:
2 Sets of Disasters Biotech Will Pay For in 2019
2 Sets of Disasters Biotech Will Pay For in 2019
Yahoo/Motley Fool
Gilead Sciences
Yescarta
Novartis
Kymriah
Spark Therapeutics
Luxturna
Flag link:
ASH: Gilead, Novartis tout long-term data for CAR-T slow starters Yescarta, Kymriah
ASH: Gilead, Novartis tout long-term data for CAR-T slow starters Yescarta, Kymriah
Fierce Pharma
Gilead
Novartis
CAR-T
Yescarta
Kymriah
ASH2018
Flag link:
Novartis’ CAR-T cancer drug available on NHS to young people
Novartis’ CAR-T cancer drug available on NHS to young people
Pharmaforum
Novartis
CAR-T
NHS
refractory B-cell acute lymphoblastic leukemia
Kymriah
Flag link:
Pages
1
2
3
next ›
last »